Libaccord
Supercooled Liquid Nitrogen for Treatment of Arrhythmia
Company Overview
Snapshot
Founded in March 2020 by Gregory Golovchiner and Yakov Nedlin, Libaccord operates with 1–10 employees. The company is currently in the R&D product stage, focusing on developing an innovative device for treating ventricular and atrial arrhythmias.
Business overview
Libaccord is a Health Tech & Life Sciences company developing an innovative medical device for treating ventricular and atrial arrhythmias. Its core technology utilizes super-cooled liquid nitrogen to achieve deep ablation, employing a novel clinical approach of scar homogenization to reduce procedure time. The solution also integrates built-in ablation depth feedback for enhanced performance and safety, serving the healthcare industry, particularly hospitals and cardiology providers, with medical devices for treatments.
Strategic signal
In January 2022, Libaccord was featured in a Haaretz article highlighting its technological approach to heart rate management. This indicates early recognition of the company's innovative solution in the medical community, signaling potential for its device in the broader cardiovascular treatment market.
Company Intelligence Q&A
- What is Libaccord's core technology?
- Libaccord develops an innovative device for treating ventricular and atrial arrhythmias using super-cooled liquid nitrogen. This technology focuses on deep ablation and scar homogenization to improve treatment efficacy and safety.
- When was Libaccord founded?
- Libaccord was founded in March 2020.
- Who are the founders of Libaccord?
- Libaccord was co-founded by Gregory Golovchiner and Yakov Nedlin.
- What is the primary focus of Libaccord's product development?
- Libaccord is focused on developing a solution for treating ventricular and atrial arrhythmias, aiming to reduce procedure time and ensure performance and safety through built-in ablation depth feedback.
- What was a notable media mention for Libaccord?
- In January 2022, Libaccord was featured in an article by Haaretz, which discussed the company's technological approach to heart rate management.